| Metformin: multi-faceted protection against cancer S Del Barco, A Vazquez-Martin, S Cufí, C Oliveras-Ferraros, ... Oncotarget 2 (12), 896, 2011 | 376 | 2011 |
| Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena B Martin-Castillo, A Vazquez-Martin, C Oliveras-Ferraros, JA Menendez Cell cycle 9 (6), 1057-1064, 2010 | 290 | 2010 |
| Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis S Cufi, A Vazquez-Martin, C Oliveras-Ferraros, B Martin-Castillo, J Joven, ... Cell cycle 9 (22), 4461-4468, 2010 | 262 | 2010 |
| Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status A Vazquez-Martin, C Oliveras-Ferraros, S Cufí, S Del Barco, ... Cell cycle 9 (18), 3831-3838, 2010 | 248 | 2010 |
| The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells A Vazquez-Martin, C Oliveras-Ferraros, SD Barco, B Martin-Castillo, ... Breast cancer research and treatment 126, 355-364, 2011 | 219 | 2011 |
| Autophagy positively regulates the CD44+CD24-/low breast cancer stem-like phenotype S Cufí, A Vazquez-Martin, C Oliveras-Ferraros, B Martin-Castillo, L Vellon, ... Cell cycle 10 (22), 3871-3885, 2011 | 209 | 2011 |
| The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells J MENENDEZ, J Joven, S Cufí, B Corominas-Faja, C Oliveras-Ferraros, ... Cell cycle 12 (8), 1166-1179, 2013 | 182 | 2013 |
| Metformin-induced preferential killing of breast cancer initiating CD44+ CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast … S Cufí, B Corominas-Faja, A Vazquez-Martin, C Oliveras-Ferraros, ... Oncotarget 3 (4), 395, 2012 | 167 | 2012 |
| Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents JA Menendez, J Joven, G Aragones, E Barrajon-Catalan, ... Cell Cycle 12 (4), 555-578, 2013 | 165 | 2013 |
| Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin) C Oliveras-Ferraros, B Corominas-Faja, S Cufí, A Vazquez-Martin, ... Cell cycle 11 (21), 4020-4032, 2012 | 163 | 2012 |
| Metformin is synthetically lethal with glucose withdrawal in cancer cells JA Menendez, C Oliveras-Ferraros, S Cufí, B Corominas-Faja, J Joven, ... Cell cycle 11 (15), 2782-2792, 2012 | 159 | 2012 |
| Micro (mi) RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and … C Oliveras-Ferraros, S Cufí, A Vazquez-Martin, VZ Torres-Garcia, ... Cell cycle 10 (7), 1144-1151, 2011 | 146 | 2011 |
| The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer S Cufí, A Vazquez-Martin, C Oliveras-Ferraros, B Corominas-Faja, ... Scientific reports 3 (1), 2469, 2013 | 139 | 2013 |
| Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs B Corominas-Faja, R Quirantes-Piné, C Oliveras-Ferraros, ... Aging (Albany NY) 4 (7), 480, 2012 | 138 | 2012 |
| Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity S Verdura, E Cuyàs, E Cortada, J Brunet, E Lopez-Bonet, ... Aging (Albany NY) 12 (1), 8, 2020 | 114 | 2020 |
| Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the … C Oliveras-Ferraros, A Vazquez-Martin, E Lopez-Bonet, B Martin-Castillo, ... International journal of oncology 33 (6), 1165-1176, 2008 | 108 | 2008 |
| Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells A Vazquez-Martin, L Vellon, PM Quiros, S Cufi, E Ruiz de Galarreta, ... Cell cycle 11 (5), 974-989, 2012 | 105 | 2012 |
| Metformin is a direct SIRT1-activating compound: computational modeling and experimental validation E Cuyàs, S Verdura, L Llorach-Parés, S Fernández-Arroyo, J Joven, ... Frontiers in endocrinology 9, 657, 2018 | 99 | 2018 |
| Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response A Vazquez-Martin, C Oliveras-Ferraros, S Cufí, B Martin-Castillo, ... Cell Cycle 10 (9), 1499-1501, 2011 | 95 | 2011 |
| Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer JA Menendez, S Cufí, C Oliveras-Ferraros, B Martin-Castillo, J Joven, ... Aging (Albany NY) 3 (11), 1063, 2011 | 94 | 2011 |
